MicroRNAs play a key role in cellular regulation and if deregulated in the development of neoplastic disorders including chronic lymphocytic leukemia (CLL). RNAs from primary cells of 50 treatment-naïve CLL patients and peripheral B-cells of 14 healthy donors were applied to miRNA-expression profiling using bead chip technology. In CLL cells a set of 7 up-and 19 down-regulated miRNAs was identified. Among the miRNAs being downregulated in CLL cells, 6 out of 10 miRNA promoters being examined showed gain of methylation as compared to normal B cell controls. Subsequent target prediction of deregulated miRNAs revealed a highly significant binding prediction at the 3´UTR of the pleomorphic adenoma gene 1 (PLAG1) oncogene. Luciferase reporter assays including site directed mutagenesis of binding sites revealed a significant regulation of PLAG1 by miR-181a, miR-181b, miR-107 and miR-424. While expression of PLAG1 mRNA was not affected, PLAG1 protein expression was shown to be significantly elevated in CLL cells as compared to the levels in healthy donor B cells. In summary, we could demonstrate disruption of miRNA-mediated translational control, partly due to epigenetic transcriptional silencing of miRNAs, with subsequent overexpression of the oncogenic transcription factor PLAG1 as a putative novel mechanism of CLL pathogenesis.
Introduction
B-cell chronic lymphocytic leukemia (CLL) is the most common leukemic disorder in the western hemisphere and is characterized by an accumulation of mature B cells in the blood, bone marrow, and secondary lymphoid organs. The clinical heterogeneity in CLL is reflected by various chromosomal aberrations, e.g. deletion of chromosome 17p
indicating highly unfavorable prognosis due to loss of p53, and, on the other hand deletion of chromosome 13q14 being associated with favorable prognosis. 1 In previous work, the localization of microRNA (miRNA) and non-coding RNA genes on chromosome 13q14 led to the assumption that down-regulation of miR-15 and -16 is mediated by deletion of the locus and subsequently leads to over-expression of BCL2. In independent approaches, miR-155 was identified to be overexpressed in basically all CLL patients, whereas down-regulation of miR-15/-16 appeared to be critical only in a subset of patients. [2] [3] [4] [5] MiRNA-mediated control of messenger-RNA stability and protein translation plays a pivotal role in the fine regulation of central cellular pathways, 6 particularly in embryonic development and cell differentiation. In the multistep development of immune cells miRNAs have been shown to be key players in differentiation, in particular the multi-step development of B-cells shows stage specific miRNA signatures. 7, 8 With regard to pathogenesis of neoplastic diseases, miRNA control of putative oncogenic target genes has been previously shown to be directly involved in malignant transformation. 9, 10 There is increasing evidence for extensive miRNA deregulations in multiple neoplasias.
However, both deregulations of miRNAs as well as the identification of their functional relevant targets and regulatory circuits in CLL pathogenesis are only partly understood and remain to be elucidated. Especially, the underlying mechanisms of predominant
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By applying miRNA profiling to CLL B cells derived from a large cohort of previously untreated CLL patients, we identified a novel group of deregulated miRNA besides previously identified alterations in CLL. Based on the predominant down-regulation of miRNAs in this cohort, we investigated genetic and epigenetic alterations as potential underlying mechanisms of the observed miRNA deregulations. As a down-stream result of miRNA deregulation, we attempted to identify miRNA target genes affected by loss of miRNA control. Surprisingly, a strong oncogenic transcription factor, pleomorphic adenoma gene 1 (PLAG1), was predicted to be a target of several deregulated miRNAs.
Indeed, over-expression of PLAG1, primarily identified to be involved in tumorigenesis by promoter swapping in pleomorphic salivary gland adenomas, could be verified in CLL.
Alterations in the axis of miRNA-mediated oncogene control by epigenetic transcriptional silencing of miRNAs might be a novel oncogenic pathway in CLL pathogenesis.
Material and Methods

Patients and cells
After informed consent, blood was obtained from patients fulfilling diagnostic criteria for CLL. Only patients without prior therapy were included in this study. Fresh 
miRNA expression analysis
BeadCHip miRNA expression assay (PAS, Illumina San Diego, CA) was carried out as previously described according to the manufacturer's protocol 11 
Methylation analysis
Isolation of genomic DNA was carried out by lysis of cells for 15 min with lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA pH 7.4) at 4°C. Cell nuclei were sedimented by centrifugation, subsequently resuspended by nuclear lysis buffer (10 mM Tris-HCl, 400 mM NaCl, 2 mM Na2-EDTA pH 8.2) and lysed by adding SDS. Proteinase K digestion was carried out overnight at 50°C. Saturated NaCl-solution was added for precipitation of proteins, after centrifugation for 30 min at 4000 rpm solved genomic DNA was isolated from the supernatant, precipitated with isopropanol, washed with 70% ethanol and dissolved in TE buffer for storage. Genomic DNA (1-2 µg) was chemically modified with sodium bisulfite using the EZ methylation kit (Zymo Research, Orange, CA, USA) according to the manufacturer's instructions. Quantitative DNA methylation analysis at single CpG units (containing one or more CpG dinucleotides) was performed by MassARRAY technique, as previously described, targeting amplicons of up to 600bp size. 12 Regions of analysis were chosen by putative promoter regions of ESTs and/or protein coding genes harboring pre-miRNAs. 13, 14 The supposed promoter activity in some of the selected regions was confirmed by genome-wide miRNA promoter analyses (7 out of 17 analyzed loci). 15 Also, arbitrarily chosen genomic regions approximately 1 kb upstream of the pre-miRNAs were analyzed in order to test whether changes in DNA methylation were specific for promoter regions.
Bisulfite-treated DNA was PCR-amplified (primer sequences given in Supplemental 
Bioinformatic and statistical analysis
The array intensity data were imported into BeadStudio v3.2 (Illumina) and a quantile normalization procedure was applied. Further analysis of differential expression was carried out using R software package and dCHIP. DNA methylation data was normalized and corrected by R software package and analyzed with Wilcoxon test by JMP (8.0, SAS inc).
For target prediction Target-Scan 4.1 (www.targetscan.org), PicTar (http://pictar.mdcberlin.de), 16 MiRDB (http://mirdb.org) 17 and miRanda (http://www.microrna.org) 18 For personal use only. on September 13, 2017. by guest www.bloodjournal.org From algorithms were applied. GeneTrail database (http://genetrail.bioinf.uni-sb.de) was accessed for functional annotation of predicted target genes. 19 SPSS, Excel, and SigmaPlot were applied for statistical analysis of data.
Results
Identification of a novel set of miRNAs reduced in CLL
To assess deregulation of global miRNA expression we profiled human miRNAs using a beadchip-based miRNA expression profiling platform. Purified B-cells from either CLL patients (n=50) or healthy controls (n=14) were assessed. All CLL patients were treatment naïve. The majority of patients presented with Binet stage A disease and showed a favorable risk profile as assessed by clinical and molecular features ( Table 1 ).
The most frequent aberration was a deletion 13q14 while only 6 of 45 patients were documented to have a homozygous deletion in this area. Comparing the total number of miRNA being expressed a significantly lower number of miRNA was detected in CLL compared to normal B cells ( Figure 1A ). The predominance of down-regulated miRNAs in CLL cells was accompanied by highly significantly lower total number of miRNAs expressed above the detection threshold in CLL patients (19.8 % vs 23.5 %; p<10 -6 ).
Applying a threshold of a median fold change larger than 2, a minimal absolute difference of signal intensity defined by the detection threshold level and a p-value minor than 0.001 in CLL patient cells, 7 miRNAs appeared to be up-regulated, whereas 19
miRNA were shown to be significantly down-regulated (Table 2 , Figure 1B and supplemental data). Applying Bonferroni´s correction due to multiple testing of miRNA probe sets underlined significant deregulation of all identified miRNAs except miR-449
and miR-565.
Additionally, for miR-21 previously demonstrated to be up-regulated in CLL 21 , we could detect the highest absolute expression values of all assessed miRNAs. However, in healthy controls the miR-21 expression was not significantly lower.
Due to the clinical heterogeneity of CLL we analyzed for differential expression of miRNAs in CLL patient subsets defined by cytogenetics and prognostic markers. We could not identify significant differentially expressed miRNA in cytogenetic defined subgroups, in particular we could not detect significant deregulation of miRNAs in patients harboring del13q14. However in CD38 positive versus negative CLL cells we could detect significantly reduced expression of miR-660. In IgVH unmutated cases a significantly reduced expression of miR-146b could be observed (supplemental data).
With regard to previous miRNA screening approaches assessing either spotted miRNAarrays, Solexa-sequencing, miRNA-cloning or RT-PCR based assays, we confirmed upregulation of miR-155 and down-regulation of miR-181a/b. We also detected heterogeneous up-regulation of miR-34a, previously being identified heterogeneously expressed in CLL and being down-regulated in CLL patients harboring del17p facilitating chemotherapy resistance. 20 We could not identify significant down-regulation of miR-15
and miR-16 except in one patient harboring a homozygous deletion of chromosome 13q14. However, the previous up-regulation of miR-155, a key regulator of B-cell ontogenesis, 21 appeared to be the most prominent up-regulated miRNA in our cohort.
Here we identified so far unknown down-regulation of a set of miRNAs in CLL such as miR-107, -424, -125a, -126 and -326. were proven to be significantly downregulated in CLL (p=0.009 and 0.00002, respectively). In summary, we identified a set of predominantly down-regulated miRNAs in CLL including several hitherto unknown deregulated miRNAs.
Deregulation of miRNAs is not associated with genomic alterations but with epigenetic transcriptional silencing
With respect to genomic localization of miRNA genes deregulated in CLL, no obvious association to known breakpoints in CLL, frequent deletions and other cytogenetic alterations was seen. At chromosome 11q, four miRNA loci (miR-130, -139a, -143, -326)
were identified, however, genomic localizations are widely distributed apart from ATM locus. In addition, only three of the CLL patients in this cohort harbored a del11q deletion, thus rendering major cytogenetic breaks unlikely as the underlying mechanism in general miRNA suppression in CLL cells.
As an alternative mechanism of miRNA downregulation, we hypothesized that epigenetic transcriptional silencing could be involved. DNA hypermethylation at promoter regions is a well known transcriptional silencing mechanism. In order to investigate whether altered DNA methylation leads to aberrant expression of miRNAs in CLL, we analyzed the DNA methylation status at known or predicted transcriptional start sites (TSSs) of pri-miRNAs. ). This is likely to reflect a consequence of global loss of methylation in CLL, as previously shown. 22 Taken together, the gain of methylation was specific to the promoter regions for downregulated miRNAs, indicating that transcriptional silencing of pri-miRNA by DNA methylation, at least in part, leads to downregulation of miRNAs during CLL pathogenesis.
For Applying these filter criteria we ranked all genes for single filter criteria and a total rank was calculated. We focused on the 167 genes ranked in the group of 5% highest total rank for further analysis of functional association. GeneTrail data base for functional annotation was assessed to the high-rank group of 167 genes revealing a highly significant over-representation of transcription factors and DNA-binding proteins Table 2 ). 26 In order to functionally focus on genes involved in malignant transformation we evaluated the functional context of the 167 predicted target genes regarding oncogenesis, proliferation, anti-apoptotic properties and cell cycle control revealing a list of 48 genes. (Supplemental Table 1) Here, the strong oncogenic transcription factor pleomorphic adenoma gene 1 (PLAG1)
was identified as the top-ranked most significant gene. 9 putative evolutionary highly conserved (including chicken) and additional 8 less conserved putative binding sites for deregulated miRNAs in CLL were identified in the 3´UTR of the PLAG1 mRNA. Here we primarily assessed the TargetScan algorithm for first prediction target genes. To verify our hypothses with an independent target prediction algorithm we performed miRNAbinding prediction of PLAG1 3´UTR in several other bioinformatic approaches. By PicTar approach miR-107, -141, -181a, 181b as for the miR-15/16/195/424/497 family were analogously predicted. 16 MiRDB also predicted miR-141, -424, -181a and -181b. 17 Finally, miRanda algorithms identified miR-107, -141, -424, -181a and 181b. 18 In conclusion, the oncogene PLAG1 showed up as a key candidate to evade miRNA control especially of the under-expressed miRNAs miR-181a, -181b, -107 and 424 in CLL leading to disturbed oncogene control in leukemia cells.
PLAG1 is under the control of miRNAs being de-regulated in CLL
To experimentally address miRNA target interaction identified above, we co-transfected the individual miRNAs (miRNA-181a, -181b, -107, -424 and -141) together with a Renilla luciferase reporter construct containing a PLAG1 3'-UTR mRNA fragment into HeLa cells. After 24 hours luciferase activities in transfected HeLa cells with and without the specific miRNAs were compared. Relative to unspecific control miRNA, co-transfection with miR-181a significantly suppressed activity of the PLAG1-3´UTR-luciferase construct
For personal use only. on September 13, 2017. by guest www.bloodjournal.org From by 43.6% (p=0.03, n=5) and in miR-181b by 48.4%, respectively (p=0.03, n=5) ( Figure   4A ). PLAG1-3´UTR-reporter construct was also significantly suppressed with 28.6% activity reduction by miR-107 (p=0.01, n=5) and 42.7% activity reduction by miR-424 (p=0.005, n=5) ( Figure 4B ). In contrast,by transfection of miR-141, being up-regulated in CLL, no significant activity reduction was seen. When combining all miRNAs simultaneously to reporter assays no additive effect outranging the sole application of miR-181a/b was seen (data not shown).
In order to examine whether the observed repression of a reporter gene by miRNAs was specifically due to the presence of predicted binding sites in the PLAG1 3'-UTR fragment, these sites were disrupted by site directed mutagenesis (Supplemental Table   3 ). For interrupting a perfect seed pairing, two nucleotides were substituted in each predicted binding site. Since there are two predicted highly conserved binding sites for miR-181a/b in the PLAG1 3´UTR, three variants were generated, in which one respectively both of these sites were mutated. For assessing the role of the predicted binding sites, the PLAG1 3'-UTR constructs with wild type (wt) or mutated binding sites were co-transfected with the corresponding miRNAs and subjected to reporter assays.
Significantly reversed binding of miRNA-181a was demonstrated in miR-181-binding site mutants PLAG1-3´UTR-mut4390 (p=0.04), -mut3500 (p=0.02) and -mut4390/3500 (p=0.0002). Similarly for miR-181b significantly reversed binding by site directed mutagenesis of predicted binding sites PLAG1-3´UTR-mut4390 (p=0.039), -mut3500 (p=0.011) and -mut4390/3500 (p=0.011) was shown ( Figure 4A ). Moreover, significantly reversed miRNA-mediated suppression of activity was also seen by miR-107-binding site mutant PLAG1-3´UTR-mut4437 (p=0.006) and miR-424-binding site mutant PLAG1-3´UTR-mut4437 (p=0.018) ( Figure 4B ). Altogether miR-181a, -181b, -107 and -424 significantly bind PLAG1-3´UTR and mutating predicted binding sites completely abrogates miRNA mediated suppression. Figure 5C ).
In conclusion, the oncogene PLAG1 shows a strong aberrant expression in CLL which is significantly elevated in comparison to healthy B-cells harboring no detectable PLAG1.
Discussion
Here we describe a novel set of 26 miRNAs significantly deregulated in CLL. In addition to miR-181a and b a total set of 19 downregulated genes was identified. Strikingly, the majority of downregulated miRNA shows hypermethylation in the respective putative transcriptional starting sites within the promoter sequence strongly suggesting epigenetic rather than mutational regulation of miRNA in CLL. In fact, except for one patient, we could not confirm wide distribution of miR-15 and mir-16 downregulation attributed to homozygous deletion of chromosome 13q14. To determine oncogenic events downstream of downregulated miRNA a computational approach revealed the novel finding of the oncogene PLAG1 to be a potential target of miRNA deregulation. In fact, we clearly demonstrate regulation of PLAG1 expression by 6 of the downregulated miRNAs (miR-181a, -181b, -107, -424, -155 and -141). As a consequence of missing miRNA regulation, PLAG1 is overexpressed in CLL.
In total the number of miRNAs detectable was significantly lower in malignant CLL cells.
This phenomenon of decreased miRNA levels in malignantly transformed cells has been
For personal use only. on September 13, 2017. by guest www.bloodjournal.org From previously described. 27, 28 Comparing our data to recently published data we could verify the down-regulation of miR-181a and miR-181b in CLL. We also showed significant upregulation of miR-155 known to be a key regulator of B-cell maturation and associated with lymphoma development. 21, 29, 30 However, miR-21 that was previously reported to be highly up-regulated in CLL was shown to be only slightly over-expressed compared to healthy donor B-cells in our screening set. 2 This difference could be partially due to different screening approaches: miRNA cloning and quantitative real-time-polymerase chain reaction (qRT-PCR) of mature miRNAs versus bead chip array technology as used by us. Furthermore, we could not detect high frequencies of miR-15 and miR-16 downregulation as previously described. 4 Nevertheless, this finding is in line with previous independent observations applying both sequencing and hybridization methods for miRNA detection. We demonstrate that gain of methylation was observed especially in the promoter regions of downregulated miRNAs, while non-promoter regions showed loss of methylation irrespective of up-or down-regulation of miRNAs in CLL. This indicates that DNA methylation could be an important mechanism of transcriptional silencing, in this case of pri-miRNA, with subsequent downregulation of mature miRNAs, although we cannot exclude that loss of methylation in some locations still has biological significance in the individual locus.
We identified several novel miRNAs being significantly deregulated in CLL. This novel group of miRNAs was assessed to predict relevant down-stream targets of miRNA in CLL. Due to the high amount of false positives by in silico prediction of binding sites for a single miRNA, we combined the integrated perspective of a deregulated cluster with
For personal use only. on September 13, 2017. by guest www.bloodjournal.org From rigorous filtering for predicted binding affinity and frequency of predicted binding sites in order to reveal high probability of miRNA-target interaction. The oncogenic zink-finger transcription factor PLAG1 was identified by application of our step-wise algorithm to be targeted by miR-181a, -181b, -107, -424, -155 and -141 . So far the PLAG1 oncogene has not been described in CLL pathogenesis. However, the well-described oncogenic potential of this transcription factor on salivary gland adenomas, breast cancer and AML pathogenesis indicate the influence of PLAG1 on malignant transformation. [31] [32] [33] was primarily identified to be involved in tumorigenesis of salivary gland adenomas by translocation and promotor swapping. 31 Although we previously identified chromosomal translocations in CLL as prognostic parameter, no significantly enhanced frequency of translocations involving the PLAG1 locus could be identified in CLL. 34 In previous gene expression profiling attempts PLAG1 was not identified as over-expressed gene in CLL.
Due to the low overall mRNA expression level and the demonstrated miRNA control mechanisms the over-expression of this oncogene was undetectable for classical screening attempts. However, we could demonstrate low detectable mRNA expression levels for PLAG1 by modern RT-PCR technique and even aberrant protein expression of PLAG1 in a significant proportion of CLL cases. In contrast, no protein expression of PLAG1 was detectable in healthy donor B cells although mRNA could be shown to be prevalent in healthy B cell control cells. We therefore hypothesized that miRNA mediated control mechanisms and their disruption are crucial for PLAG1 oncogene overexpression in CLL.
We showed inhibitory potential of predicted miRNAs on the PLAG1 3´UTR by luciferase reporter assays. Moreover, site-directed mutagenesis of binding sites could demonstrate specificity of miRNA-3´UTR interaction by abrogation of miRNA regulatory effects. As a consequence for deregulation of miRNAs and disrupted control of PLAG1 3´UTR by the down-regulated miR-107, -424, -181a and 181b, we demonstrated for the first time over- . 39 Aberrant expression of VEGF in CLL leading to autostimulatory loops have been previously described and elevated bcl-2 is a key phenomenon of apoptosis resistance in CLL. 40 The overexpression of PLAG1 dependent genes indicates regulatory effects of PLAG1 as oncogenic transcription factor in CLL, however ongoing research efforts using transgenic mice models will reveal the oncogenic potential of PLAG1 in B cells. analyzed the data; C.P.P. and C.-M.W. wrote the paper.
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